NEWS

Auransa Announcements

Featured

First patient in Asia receives AU409 following the ongoing first-in-human clinical trial in the US for liver cancer

Aug 7, 2024

First patient in Asia receives AU409 following the ongoing first-in-human clinical trial in the US for liver cancer

Aug 7, 2024

Aug 7, 2024

Seven AI/ML for Life Sciences Companies Identified as Innovators in New Seven AI/ML for Life Sciences Companies Identified as Innovators in New Clarivate Companies to Watch Report

Sep 27, 2023

Seven AI/ML for Life Sciences Companies Identified as Innovators in New Seven AI/ML for Life Sciences Companies Identified as Innovators in New Clarivate Companies to Watch Report

Sep 27, 2023

Sep 27, 2023

AI-Biopharma Auransa Announces Successful First Patient Dosed in Phase 1 Clinical Trial for Liver Cancer

Sep 14, 2023

AI-Biopharma Auransa Announces Successful First Patient Dosed in Phase 1 Clinical Trial for Liver Cancer

Sep 14, 2023

Sep 14, 2023

USC Norris collaborates with Auransa on clinical trial of new targeted treatment for liver cancer and other solid tumors

Mar 23, 2023

USC Norris collaborates with Auransa on clinical trial of new targeted treatment for liver cancer and other solid tumors

Mar 23, 2023

Mar 23, 2023

FDA Acceptance of Auransa's IND Application for AU409 for Treatment of Patients with Hepatocellular Carcinoma

Nov 3, 2022

FDA Acceptance of Auransa's IND Application for AU409 for Treatment of Patients with Hepatocellular Carcinoma

Nov 3, 2022

Nov 3, 2022

POLARISqb and Auransa Announce Promising Results for Triple Negative Breast Cancer using Quantum Computing and AI

Aug 9, 2022

POLARISqb and Auransa Announce Promising Results for Triple Negative Breast Cancer using Quantum Computing and AI

Aug 9, 2022

Aug 9, 2022

Auransa and POLARISqb enter research collaboration finding treatments for neglected women's diseases

Jun 4, 2021

Auransa and POLARISqb enter research collaboration finding treatments for neglected women's diseases

Jun 4, 2021

Jun 4, 2021

AU-409: a Novel, AI-Derived Drug Candidate for the Treatment of Hepatocellular Carcinoma

Sep 23, 2019

AU-409: a Novel, AI-Derived Drug Candidate for the Treatment of Hepatocellular Carcinoma

Sep 23, 2019

Sep 23, 2019

Auransa Enters into Exclusive Licensing Agreement with China Oncology Focus Limited, an Affiliate of Lee’s Pharmaceutical Holdings, for Rights to AU018 in Greater China and Southeast Asia

Dec 19, 2018

Auransa Enters into Exclusive Licensing Agreement with China Oncology Focus Limited, an Affiliate of Lee’s Pharmaceutical Holdings, for Rights to AU018 in Greater China and Southeast Asia

Dec 19, 2018

Dec 19, 2018

Interested in working together?